TCL Archive Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial April 27, 2012
TCL Archive Broder’s Conundrum: How To Let Congress Know NCI Needs More Money Without Asking For it March 17, 1989
TCL Archive Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies November 28, 2014
TCL Archive NCCN and Pfizer Issue RFP In Renal Cell Carcinoma Or Hematologic Malignancies October 25, 2013
